SH-11037
SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization.
For research use only. We do not sell to patients.
- CAS No.: 1638153-78-2
- Formula: C34H39NO10
- Molecular Weight:621.67
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[4]|
sEH |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ARPE-19 | GI50 |
100 μM
Compound: SH-11037
|
Cytotoxicity against human ARPE-19 cells assessed as cell growth inhibition incubated for 44 hrs by AlamarBlue reagent based fluorescence assay
Cytotoxicity against human ARPE-19 cells assessed as cell growth inhibition incubated for 44 hrs by AlamarBlue reagent based fluorescence assay
|
[PMID: 36938984] |
In Vitro
SH-11037 (14a) potently and selectively inhibits the proliferation of human microvascular retinal endothelial cells (HRECs) with a GI50 of 0.055 μM, showing ~14-fold selectivity over HUVECs, >1000-fold selectivity over 92-1 cells, and ~218-fold selectivity over Y79 cells[1].
SH-11037 dose-dependently inhibits human microvascular retinal endothelial cell (HREC) proliferation without inducing apoptotic nuclear changes[1].
SH-11037 (30-600 nM) dose-dependently inhibits the migration of human microvascular retinal endothelial cells (HRECs) in a scratch wound assay, with significant inhibition observed at concentrations ≥300 nM[1].
SH-11037 (30-500 nM) dose-dependently inhibits the tube formation of human microvascular retinal endothelial cells (HRECs) on Matrigel, with significant inhibition observed at concentrations ≥100 nM[1].
SH-11037 (50-600 nM) induces minimal apoptosis in human microvascular retinal endothelial cells (HRECs), with <10% of cells undergoing apoptosis at concentrations up to 600 nM[1].
SH-11037 (30-1000 nM) does not reduce the viability of human microvascular retinal endothelial cells (HRECs)[1].
SH-11037 (100-1000 nM; 48 h) causes a dose-dependent G2/M phase cell cycle arrest in human microvascular retinal endothelial cells (HRECs) without significant induction of apoptosis[1].
SH-11037 (1 μM; up to 2 h) is stable in pH 7.4 phosphate buffer but undergoes rapid, quantitative enzymatic hydrolysis to SH-11008 in mouse plasma (half-life 0.018 min) and slower hydrolysis in dog (half-life 69.1 min) and human plasma (half-life 73.2 min)[2].
SH-11037 (1 μM; up to 2 h) has carboxylesterase as the predominant enzyme mediating rapid hydrolysis to SH-11008 in mouse plasma and mouse eye homogenate; paraoxonase 1 and butyrylcholinesterase mediate slower hydrolysis in dog plasma, while only paraoxonase 1 mediates hydrolysis in human plasma[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human microvascular retinal endothelial cells
-
Concentration:100 nM; 300 nM; 1000 nM
-
Incubation Time:48 h
-
Result:Arrested HRECs at the G2/M phase of the cell cycle.
In Vivo
SH-11037 (1-10 μM) inhibits ocular angiogenesis in zebrafish larvae[4].
SH-11037 (0.1-100 μM; i.v.; single dose) has no toxic effects to eye[4].
SH-11037 (0.1-10 μM; i.v.; single dose) dose-dependently suppresses choroidal neovascularisation (CNV) lesion volume[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (male, 8 weeks old, 30~35 g)[2]
-
Dosage:5 mg/kg
-
Administration:i.v.; single dose
-
Result:Exhibited plasma levels below quantitation limit (<0.24 ng/mL) throughout 24-hour time course.
Produced hydrolytic metabolite with peak concentration (Cmax) of 738.1 ng/mL at 5 minutes, area under the curve (AUCinf) of 14,728.5 ng·min/mL, and half-life (t1/2) of 3.6 minutes, detected above quantitation limit up to 30 minutes.
Reached fraction converted to fm of 102.7%.
-
Animal Model:ICR (male, 8 weeks old, 30~35 g)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose
-
Result:Showed plasma levels below quantitation limit throughout 24-hour time course.
-
Animal Model:C57BL/6J (female, 6-8 weeks)[4]
-
Dosage:0.1 μM; 1 μM; 10 μM; 100 μM
-
Administration:i.v.; single dose
-
Result:Showed no histological changes in retinal sections.
Showed no morphological changes to retinal thickness.
Showed no signs of retinal injury, apoptosis or inflammation.
-
Animal Model:C57BL/6J (female, 6-8 weeks)[4]
-
Dosage:0.1 μM; 0.3 μM; 1 μM; 10 μM
-
Administration:i.v.; single dose
-
Result:Reduced CNV lesion size at 1 and 10 μM compared to vehicle controls.
Reduced leakiness of CNV lesions relative to the vehicle treatment.
Chemical Information
-
CAS No. 1638153-78-2
-
Molecular Weight 621.67
-
Formula C34H39NO10
-
SMILES
COC1=C2C(OCC(C2=O)CC3=CC(OC([C@@H](NC(OC(C)(C)C)=O)CC4=CC=CC=C4)=O)=C(C=C3)OC)=CC(OC)=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Basavarajappa HD, et al. Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization. J Med Chem. 2015;58(12):5015-5027. [Content Brief]
[2]. Kim EY, et al. Mouse Pharmacokinetics and In Vitro Metabolism of SH-11037 and SH-11008, Synthetic Homoisoflavonoids for Retinal Neovascularization. Pharmaceutics. 2022;14(11):2270. Published 2022 Oct 24. [Content Brief]
[3]. Sulaiman RS, et al. Chemical Proteomics Reveals Soluble Epoxide Hydrolase as a Therapeutic Target for Ocular Neovascularization. ACS Chem Biol. 2018 Jan 19;13(1):45-52. [Content Brief]
[4]. Sulaiman RS, et al. A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy. Sci Rep. 2016 May 5;6:25509. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)